156 related articles for article (PubMed ID: 18423057)
1. Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.
Lolis N; Veldekis D; Moraitou H; Kanavaki S; Velegraki A; Triandafyllidis C; Tasioudis C; Pefanis A; Pneumatikos I
Crit Care; 2008; 12(2):414. PubMed ID: 18423057
[TBL] [Abstract][Full Text] [Related]
2. Saccharomyces cerevisiae fungemia after probiotic treatment in an intensive care unit patient.
Kara I; Yıldırım F; Özgen Ö; Erganiş S; Aydoğdu M; Dizbay M; Gürsel G; Kalkanci A
J Mycol Med; 2018 Mar; 28(1):218-221. PubMed ID: 29132794
[TBL] [Abstract][Full Text] [Related]
3. Kodamaea ohmeri fungaemia successfully treated with caspofungin.
Chiu CH; Wang YC; Shang ST; Chang FY
Int J Antimicrob Agents; 2010 Jan; 35(1):98-9. PubMed ID: 19896340
[No Abstract] [Full Text] [Related]
4. Seven cases of Saccharomyces fungaemia related to use of probiotics.
Roy U; Jessani LG; Rudramurthy SM; Gopalakrishnan R; Dutta S; Chakravarty C; Jillwin J; Chakrabarti A
Mycoses; 2017 Jun; 60(6):375-380. PubMed ID: 28133894
[TBL] [Abstract][Full Text] [Related]
5. Septic Candida krusei thrombophlebitis of inferior vena cava with persistent fungemia successfully treated by new antifungal agents.
Pan SC; Hsieh SM; Chang SC; Lee HT; Chen YC
Med Mycol; 2005 Dec; 43(8):731-4. PubMed ID: 16422304
[TBL] [Abstract][Full Text] [Related]
6. Saccharomyces boulardii probiotic-associated fungemia: questioning the safety of this preventive probiotic's use.
Martin IW; Tonner R; Trivedi J; Miller H; Lee R; Liang X; Rotello L; Isenbergh E; Anderson J; Perl T; Zhang SX
Diagn Microbiol Infect Dis; 2017 Mar; 87(3):286-288. PubMed ID: 28024866
[TBL] [Abstract][Full Text] [Related]
7. Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum.
Santino I; Alari A; Bono S; Teti E; Marangi M; Bernardini A; Magrini L; Di Somma S; Teggi A
Int J Immunopathol Pharmacol; 2014; 27(1):143-6. PubMed ID: 24674691
[TBL] [Abstract][Full Text] [Related]
8. [Saccharomyces boulardii fungal sepsis: beware of the yeast].
Piechno S; Seguin P; Gangneux JP
Can J Anaesth; 2007 Mar; 54(3):245-6. PubMed ID: 17331940
[No Abstract] [Full Text] [Related]
9. Saccharomyces cerevisiae fungemia: Risk factors, outcome and links with S. boulardii-containing probiotic administration.
Poncelet A; Ruelle L; Konopnicki D; Miendje Deyi VY; Dauby N
Infect Dis Now; 2021 May; 51(3):293-295. PubMed ID: 33934809
[TBL] [Abstract][Full Text] [Related]
10. Invasive infections due to Saccharomyces boulardii (Ultra-levure).
Prescrire Int; 2007 Jun; 16(89):110. PubMed ID: 17582930
[TBL] [Abstract][Full Text] [Related]
11. Possible role of catheters in Saccharomyces boulardii fungemia.
Hennequin C; Kauffmann-Lacroix C; Jobert A; Viard JP; Ricour C; Jacquemin JL; Berche P
Eur J Clin Microbiol Infect Dis; 2000 Jan; 19(1):16-20. PubMed ID: 10706174
[TBL] [Abstract][Full Text] [Related]
12. [Saccharomyces cerevisiae fungemia in an elderly patient following probiotic treatment].
Eren Z; Gurol Y; Sonmezoglu M; Eren HS; Celik G; Kantarci G
Mikrobiyol Bul; 2014 Apr; 48(2):351-5. PubMed ID: 24819274
[TBL] [Abstract][Full Text] [Related]
13. Resolution of fungemia due to Fusarium species in a patient with acute leukemia treated with caspofungin.
Apostolidis J; Bouzani M; Platsouka E; Belasiotou H; Stamouli M; Harhalakis N; Boutati EI; Paniara O; Nikiforakis E
Clin Infect Dis; 2003 May; 36(10):1349-50. PubMed ID: 12746788
[No Abstract] [Full Text] [Related]
14. Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France.
Blanchard E; Lortholary O; Boukris-Sitbon K; Desnos-Ollivier M; Dromer F; Guillemot D;
Antimicrob Agents Chemother; 2011 Nov; 55(11):5358-61. PubMed ID: 21859944
[TBL] [Abstract][Full Text] [Related]
15. [Three cases of fungemia caused by Blastoschizomyces capitatus].
Koç AN; Copur Çiçek A; Kaynar L; Sav H; Kasap Tekinşen FF; Atalay MA
Mikrobiyol Bul; 2013 Oct; 47(4):734-41. PubMed ID: 24237444
[TBL] [Abstract][Full Text] [Related]
16. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.
Cleary JD; Garcia-Effron G; Chapman SW; Perlin DS
Antimicrob Agents Chemother; 2008 Jun; 52(6):2263-5. PubMed ID: 18378714
[TBL] [Abstract][Full Text] [Related]
17. Breakthrough Trichosporon asahii fungemia in neutropenic patient with acute leukemia while receiving caspofungin.
Bayramoglu G; Sonmez M; Tosun I; Aydin K; Aydin F
Infection; 2008 Feb; 36(1):68-70. PubMed ID: 17882360
[TBL] [Abstract][Full Text] [Related]
18. Plasma concentrations of caspofungin in a critically ill patient with morbid obesity.
Ferriols-Lisart R; Aguilar G; Pérez-Pitarch A; Puig J; Ezquer-Garín C; Alós M
Crit Care; 2017 Aug; 21(1):200. PubMed ID: 28764793
[No Abstract] [Full Text] [Related]
19. Breakthrough Fusarium spp fungemia during caspofungin therapy in an ABO-incompatible orthotopic liver transplant patient.
Tascini C; Urbani L; Doria R; Catalano G; Leonildi A; Filipponi F; Menichetti F
J Chemother; 2009 Apr; 21(2):236-8. PubMed ID: 19423484
[No Abstract] [Full Text] [Related]
20. Breakthrough Candida dubliniensis fungemia in an acute myeloid leukemia patient during voriconazole therapy successfully treated with caspofungin.
Fanci R
J Chemother; 2009 Feb; 21(1):105-7. PubMed ID: 19297283
[No Abstract] [Full Text] [Related]
[Next] [New Search]
